Sign in

You're signed outSign in or to get full access.

Ronald Hundzinski

Chairman of the Board at InfuSystem Holdings
Board

About Ronald Hundzinski

Ronald Hundzinski, age 66, joined InfuSystem’s Board on November 12, 2024. He is a veteran public-company CFO and finance leader with 40+ years across automotive and industrials, and currently serves as Chairman of the Board at Gentherm, Inc. He holds a BBA in Finance from Western Michigan University and an MBA from the University of Colorado .

Past Roles

OrganizationRoleTenureCommittees/Impact
TI Fluid SystemsChief Financial Officer; Executive DirectorJan 2020 – Apr 2023Public-company CFO; board-level finance oversight
Tenneco Inc.EVP, FinanceJan 2018 – Dec 2019Corporate finance leadership
BorgWarner, Inc.EVP & CFO (2012–2018); prior roles incl. Treasurer, PAO, VP Finance (Turbo Systems)Various; CFO 2012–2018Deep accounting, internal controls, capital markets; operating finance

External Roles

CompanyRoleSinceIndustry/Notes
Gentherm, Inc.Director; Chairman of the BoardDirector since 2016; Chairman currentThermal management and pneumatic comfort technologies for automotive and medical industries

Board Governance

  • Independence: The Board affirmed Hundzinski is an Independent Director under NYSE American standards (all directors except the President/COO were deemed independent) .
  • Committees: Member, Audit Committee (members: Gendron—Chair, Eichenbaum, Hundzinski, Huss). Audit held 8 meetings in FY2024; all members were independent and compliant with Rule 10A‑3; Gendron designated audit committee financial expert .
  • Attendance: The Board met 6 times in FY2024; each director attended at least 75% of Board and applicable committee meetings. Independent director executive sessions were held at each regularly scheduled Board meeting and chaired by the independent Chairman .
  • Leadership: Separate CEO and Chairman roles; Chairman is independent .

Fixed Compensation

DirectorYearFees Earned (Cash)Notes
Ronald Hundzinski2024$8,219Pro‑rated cash fees following appointment on Nov 12, 2024 .

Director cash fee schedule in 2024 (paid quarterly): $50,000 per independent director; $90,000 Board Chair; Audit Chair $20,000 / members $10,000; Compensation Co‑Chairs $10,000 each / members $5,000; Nominating Chair $10,000 / members $5,000 .

Performance Compensation

Grant TypeShares/UnitsExercise/StrikeGrant ContextVestingExpirationGrant-Date Fair Value
Stock Options13,264$9.51Granted upon Board appointment (Nov 12, 2024)Vests over 1 year; accelerates upon change in control under 2021 Equity PlanNov 12, 2034$55,483 .

Notes:

  • Standard 2024 director equity was options for 35,685 shares each; exception applied to Hundzinski due to mid‑year appointment .
  • Options granted at closing price on grant date; one‑year vest or immediate on change in control per plan .

Other Directorships & Interlocks

RelationshipDetailPotential Overlap
Gentherm, Inc.Chairman; Director since 2016; automotive/medical thermal technologiesINFU’s business focuses on DME services and biomedical support; no related-party transactions reported for FY2023–FY2024 .

Expertise & Qualifications

  • Extensive CFO/finance leadership across multiple public companies; strengths in accounting, internal controls, capital markets, M&A and operating finance .
  • Adds depth to INFU Board oversight and committee work as Company diversifies its business .
  • Audit Committee member; not designated the committee’s “financial expert” (that designation is held by Paul Gendron) .

Equity Ownership

HolderDirect SharesOptions Exercisable/Within 60 DaysRSUs/PSUs Vesting ≤60 DaysTotal Beneficial Ownership% of Outstanding
Ronald Hundzinski13,26413,264<1% (based on 21,016,415 shares o/s as of Mar 20, 2025) .

Policy constraints on alignment risk:

  • Hedging and pledging: Company policy strongly discourages hedging and prohibits holding INFU stock in margin accounts or pledging as loan collateral; pre‑clearance required for any monetization transactions .

Governance Assessment

  • Strengths: Independent director with deep CFO and internal controls background; immediate integration to Audit Committee; Board/committee independence and executive sessions; no related‑party transactions reported in FY2023–FY2024; anti‑hedging and anti‑pledging policy in place .
  • Watch items: Short INFU tenure (appointed Nov 12, 2024), and modest current beneficial ownership limited to options (13,264; <1%)—monitor future equity accumulation for alignment signals .
  • Committee workload/engagement: Audit Committee met 8 times in FY2024; Board reported all directors met ≥75% attendance requirements, indicating baseline engagement .

Related-Party Exposure and Policies

  • Related-party transactions: None required to be reported under Item 404(d) for FY2023 and FY2024 .
  • Clawback: Company maintains a clawback policy compliant with SEC/NYSE requirements—applies to incentive-based compensation for covered executives (NEOs). Not specified for non‑employee directors .
  • Equity plan/change in control: Director stock options vest immediately upon a change in control under the 2021 Equity Plan .

Director Compensation (Cross-Reference)

DirectorYearFees Earned (Cash)Option Awards (Grant-Date FV)Total
Ronald Hundzinski2024$8,219$55,483$63,702 .

Attendance and Independence (Cross-Reference)

MetricDisclosure
Board meetings held (FY2024)6
Audit Committee meetings (FY2024)8
Director attendanceEach director attended ≥75% of Board and committee meetings served
IndependenceAll directors except the President/COO are independent (includes Hundzinski)